Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Ultrasound renal denervation for uncontrolled high blood pressure after kidney transplant

Official title: Safety and Efficacy of Ultrasound Renal Denervation in Kidney Transplantation Patients With Uncontrolled Hypertension: the RESTART Study

Run by Erasmus Medical Center · NCT05934383 · Data updated 2026-11-12

This study will try ultrasound renal denervation on the native kidneys to see if it lowers blood pressure in kidney transplant patients whose hypertension is not controlled by medicines.

More Hypertension trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment40 (estimated)
SponsorErasmus Medical Center
Academic / other
Locations1 site (Rotterdam)
StatusRecruiting
StartedSeptember 4, 2023
Main results expectedJanuary 2026
Study endsSeptember 2030
Registry record updatedJune 26, 2025
Trial IDNCT05934383 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults at least 12 months after kidney transplant with stable immunosuppression, eGFR ≥40 ml/min/1.73m2, and persistent high office and 24-hour ambulatory systolic blood pressure despite a stable regimen of at least two antihypertensives (including a diuretic) or documented intolerance to multiple drug classes.

Probably not a fit

Patients with unsuitable native renal artery anatomy (for example prior renal artery stenting or prior RDN), low eGFR, recent transplant or those whose blood pressure is already controlled on medication are unlikely to benefit from this procedure.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-arm study enrolling 40 kidney transplant recipients with uncontrolled hypertension despite medication (or documented medication intolerance) to receive bilateral ultrasound renal denervation of their native kidneys using the Paradise® system. Participants must be at least 12 months post-transplant, have stable immunosuppression and an eGFR ≥40 ml/min/1.73m2. The study will track office and 24-hour ambulatory blood pressure, antihypertensive medication use and adherence, and procedure safety over short-term and long-term follow-up. Results will address a gap because prior randomized RDN trials excluded patients with prior renal failure or transplantation.

Why it matters

Potential benefit: If successful, the procedure could lower blood pressure and potentially reduce the need for antihypertensive drugs in transplant recipients, which may lower cardiovascular risk and help preserve graft function.

How similar studies have gone: Randomized trials in non‑transplant populations have shown that renal denervation can safely lower blood pressure, but kidney transplant recipients were excluded from those trials so its effect in this group is currently untested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥ 18 years
* Kidney transplantation ≥ 12 months ago with stable immunosuppressive drug treatment
* Estimated Glomerular Filtration Rate (eGFR) ≥ 40 ml/min/1.73m2
* Office systolic BP ≥ 140 mmHg and a mean 24-hour ambulatory systolic BP ≥ 130 mmHg at screening
* Antihypertensive medication regimen:

  * Stable regimen of at least two antihypertensive drugs of different classes, including a diuretic (defined a thiazide diuretic, loop diuretic or mineralocorticoid receptor antagonist), for at least three months, or
  * Documented intolerance to three classes of antihypertensive drugs, and
  * A change in antihypertensive drug regimen is not anticipated within the oncoming three months.
* Patient is willing and able to provide written informed consent

Exclusion Criteria:

* Native renal artery anatomy not eligible for RDN, defined as at least one of the following conditions:

  * History of renal artery stenting or angioplasty
  * History of renal denervation
  * History of kidney tumors
  * Renal artery diameter \< 3 mm or \> 8 mm
  * Renal artery length \< 20 mm
  * Fibromuscular disease (FMD) of the native renal arteries
  * Renal artery aneurysm
  * Renal artery stenosis \> 30%
* Presence of a remnant transplant kidney after re-transplantation or absence of native kidneys
* Solitary native kidney
* History of intravenous contrast dye allergy or nephropathy
* Iliac/femoral artery stenosis precluding insertion of the Paradise catheter
* Uncorrected, treatable secondary cause of hypertension
* Pregnancy
* Life expectancy \< one year at the discretion of the investigator

Where it's running

  • Erasmus University Medical Center
    Rotterdam, Netherlands
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.